Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
45 /100
MEDIUM RISK
Score updated Oct 13, 2026

NSRX — Nasus Pharma Ltd. Dilution Risk Tracker

Track NSRX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track NSRX — Get alerts when the score changes →

As of October 13, 2026, Nasus Pharma Ltd. (NSRX) has a DilutionWatch DilutionScore of 45/100, rated MEDIUM dilution risk. Nasus Pharma Ltd. has a market capitalization of $29.93M, 9.02M shares outstanding, 9 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
42
💰 Cash Runway
40
📊 Float Risk
42
⚠️ Warrant Exposure
40
🔄 Convertible Debt
15

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for NSRX.
🔔 Track NSRX — Get forecast alerts →

Market Data

Market Cap$29.93M
Shares Outstanding9.02M
Float4.86M
Cash$1.24M
Debt$118.0K
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore45/100DilutionWatch score record
Shares Outstanding9.02MVerified float table or market cache
Public Float4.86MVerified float table or market cache
Market Cap$29.93MMarket data cache
Cash Runway17.1 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 1.

Recent SEC source mix: XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

9 institutional holders · 2.18M shares
#1 Balyasny Asset Management L.P. 898.5K shares
#2 Cable Car Capital, LP 602.0K shares
#3 Velan Capital Investment Management LP 359.4K shares
+ 6 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest78.2K
Days to Cover2.9
% of Float1.6%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2026-03-25
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual NSRX Dilution Snapshot

Nasus Pharma Ltd. (NSRX) has a DilutionScore of 45/100, rated Medium dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

NSRX's DilutionScore is currently 45/100 (Medium risk), with 3 score changes tracked over 89 days. The score deteriorated from 59/100 (High risk).

Period Score Risk Level Duration
Oct 13, 202645/100MEDIUM1 day
Aug 22 – Oct 12, 202659/100HIGH52 days
Aug 14 – Aug 21, 202658/100HIGH7 days
Jul 16 – Aug 13, 202654/100HIGH29 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

NSRX shares outstanding have decreased 0.0% from 11.71M (Mar 2026) to 11.71M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 30, 202611.71M4.86M▲ 5.59%
May 24, 202611.71M4.61M▼ 0.06%
May 18, 202611.71M4.61M▼ 16.15%
Apr 23, 202611.71M5.50M▼ 0.65%
Apr 11, 202611.71M5.53M▼ 9.98%
Apr 03, 202611.71M6.14M▼ 0.58%
Apr 01, 202611.71M6.18M▲ 29.77%
Mar 26, 202611.71M4.76M▲ 22.44%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track NSRX Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment NSRX files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking NSRX — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for NSRX
NSRX FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.